- 期刊
Eight Kinds of Chinese Patent Medicine for Non‐alcoholic Fatty Liver Disease: A Network Meta‐analysis
摘要
Objective: To evaluate the clinical effectiveness and safety of eight kinds of Chinese patent medicine in the treatment of non‐alcoholic fatty liver disease (NAFLD) by network meta‐analysis. Methods: The following databases such as CNKI, VIP, CBM, Wanfang Database, PubMed, Embase and Cochrane library were searched from the establishment date to March 2021, to collect all published randomized controlled trials of Chinese patent medicine in the treatment of NAFLD. The literature screening, data extraction were all conducted independently by two reviewers and analysed using STATA version 15.0. The methodological quality of the included studies was evaluated using the Cochrane risk of bias tool. Results: 23 studies encompassing 2431 patients were included. The results revealed that Huazhi Rougan Granules, Kezhi Capsules, Silibinin Capsules are more effective in improving TC on the comparison of other Chinese patent medicine; Huazhi Rougan Granules, Qianggan Capsules, Kezhi Capsules are more effective in improving TG on the comparison of other Chinese patent medicine; Huazhi Rougan Granules, Liuweiwuling Tablets, Silibinin Capsules are more effective in improving ALT and AST on the comparison of other Chinese patent medicine. Conclusion: The current evidence demonstrated that Huazhi Rougan Granules might be the most effective Chinese patent medicine in the treatment of NAFLD. Due to the limitations of the original study, further studies that are high in quality and adequately powered are needed to confirm these findings. It is recommended that clinical actual conditions and traditional Chinese medicine syndrome differentiation should be considered in the selection of Chinese patent medicine.